According to a new
market report published by Transparency Market Research "Dilated
Cardiomyopathy Therapeutics Market - Global Industry Analysis,
Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 -
2020," the global dilated cardiomyopathy market was valued at
USD 651.0 million in 2013 and is estimated to reach USD 328.6 million
in 2020 declining at a CAGR of (7.0%) from 2014 to 2020.
Browse the full
report Dilated Cardiomyopathy Therapeutics Market at
http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
Dilated
cardiomyopathy (DCM) is one of the myocardium disorders associated
with cardiac dysfunction. Hypertrophic, dilated, arrhythmogenic right
ventricular and restrictive cardiomyopathies represent the four major
types of cardiomyopathies, and the others fall under unclassified
category. DCM accounts for one of the major causes of heart failure
and is characterized by the presence of dilated heart muscles which
lead to enlargement of the heart. This in turn, hampers blood pumping
capacity of the heart and with time, DCM spreads to the right
ventricle, atria and ultimately results in heart failure. The
occurrence of dilated cardiomyopathy in males is more prevalent than
in females at a ratio of 3:1. Patients with mild DCM can lead normal
lives by regular intake of medication along with some lifestyle
changes, while patients with severe DCM need a heart transplant.
Oral medications and
implantable medical devices constitute the key treatment options for
DCM. Oral medications decrease the size of the heart by acting
against high blood pressure and coronary artery disease. Devices
implanted in DCM patients refer to implantable
cardioverter–defibrillator (ICD), pacemakers (biventricular pacing)
and heart pumps. The dilated cardiomyopathy therapeutics market is
anticipated to decline throughout the forecast period from 2014 to
2020. This is majorly attributed to patent expirations, potential
side effects of the drugs and increasing efficiency of alternative
therapies.
The market for
dilated cardiomyopathy therapeutics is segmented majorly by drug
class and geography. The various drug classes considered include
aldosterone antagonists, angiotensin converting enzyme (ACE)
inhibitors, angiotensin II receptor blockers and beta blockers. ACE
inhibitors are considered as the first line of treatment in patients
suffering from dilated cardiomyopathy, and these drugs help improve
pumping capacity of the heart by decreasing the activity of
rennin-angiotensin-aldosterone system (RAAS). The sales of ACE
inhibitors are anticipated to reduce during the forecast period from
2014 to 2020 majorly due to patent expiration of the prominent drugs
and increasing competition from generic drugs, which will further
hamper market growth.
Aldosterone
antagonists reduce cardiac activity and blood pressure. Eplerenone
and spironolactone are the two major aldosterone antagonists used in
the treatment of dilated cardiomyopathy. This drug class will record
highest growth rate owing to their increased acceptance and increased
survival rate of patients with DCM. Angiotensin II receptor blockers
(ARBs) in combination with ACE inhibitors are usually preferred to
treat dilated cardiomyopathy as these drugs block the RAAS pathway,
thereby reducing the pressure exerted by the heart. Clinical trials
have proven the successful effect of ARBs such as valsartan, losartan
and candersartan against DCM. However, loss of patent exclusivity of
major drugs followed by the increased efficiency of combination
therapies in treatment of DCM might hamper market growth and result
in declined sales in the forthcoming years.
Currently, there is
no drug approved specifically for the treatment of dilated
cardiomyopathy; however, the above mentioned drugs have been studied
for their effectiveness in treatment of DCM that has lead to doctors
prescribing these medications. This factor provides lucrative
opportunity for the market payers to develop and commercialize
specific drugs against dilated cardiomyopathy. Increasing efficiency
of alternative therapies such as implantable medical devices and gene
therapy might further play a role in decelerating market growth.
Major players
competing in this market are Novartis International AG, Merck Co. &
Inc., and AstraZeneca plc that together accounted for more than 70%
of the total dilated cardiomyopathy therapeutics market revenue.
Other players include Pfizer, Inc., Sanofi Aventis, GlaxoSmithKline
plc and Valeant Pharmaceuticals, Inc. Increasing investments by
market players towards the development of dilated cardiomyopathy
drugs will favor market growth post their approval. For instance,
Array BioPharma, Inc. (ARRY – 797), Celladon Corporation (MYDICAR)
and Vericel Corporation (IXCELL-DCM, Catheter-DCM, IMPACT-DCM)
constitute some of the companies whose drugs are in pipeline (phase I
or Phase II).
Browse the full
Press Release report:
The global dilated
cardiomyopathy therapeutics market is segmented into the following
categories:
Dilated
cardiomyopathy therapeutics market, by drug class
Aldosterone
antagonists
Angiotensin-converting
enzyme (ACE) inhibitors
Angiotensin II
receptor blockers (ARBs)
Beta-blockers
Dilated
cardiomyopathy therapeutics market, by pipeline drugs
ARRY-797
ixCELL-DCM
MYDICAR
OR-1
CAP-1002
Dilated
cardiomyopathy therapeutics market, by geography
North America
Europe
Asia Pacific
Rest of the World
(RoW)
Request a Brochure
of this
Report http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2293
About Us
Transparency Market
Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. Our experienced team of
Analysts, Researchers, and Consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.
Our data repository
is continuously updated and revised by a team of research experts, so
that it always reflects the latest trends and information. With a
broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in
developing distinctive data sets and research material for business
reports.
No comments:
Post a Comment